Literature DB >> 7717218

Portal vein thrombosis after percutaneous ethanol injection for hepatocellular carcinoma: value of color Doppler sonography in distinguishing chemical and tumor thrombi.

R Lencioni1, D Caramella, F Sanguinetti, L Battolla, F Falaschi, C Bartolozzi.   

Abstract

OBJECTIVE: The distinction between benign (chemical) and tumor thromboses of the portal vein after treat,ent with percutaneous injection of ethanol for hepatocellular carcinoma is crucial for the proper management of the patient. The purpose of this study was to determine whether color Doppler sonography can be used to differentiate between the two types of thrombi. SUBJECTS AND METHODS: Between October 1991 and April 1994, portal vein thrombosis was detected by color Doppler sonography in 19 patients (13 men and six women 59-77 years old; mean age, 67 years) who had hepatocellular carcinomas and who had received percutaneous ethanol injection (n = 11) or percutaneous ethanol injection after transcatheter arterial embolization (n = 8). The criterion for diagnosing tumor thrombosis by color Doppler sonography was the detection of pulsatile arterial flow in the thrombus. The benign or malignant nature of the thrombosis was subsequently established by percutaneous fine-needle biopsy of the thrombus; malignant thrombosis was seen in 13 patients, and chemical thrombosis was seen in six patients.
RESULTS: Pulsatile arterial flow in the thrombus was observed by color Doppler sonography in 12 of the 13 malignant thrombi and in none of the bland thrombi. The flow was hepatopetal in seven cases and hepatofugal in five cases. The peak systolic frequency shift ranged from 0.59 to 2.65 kHz (mean, 1.35 kHz), and the resistive index ranged from 0.37 to 0.69 (mean, 0.55). The sensitivity and the specificity of color Doppler sonography for the detection of tumor thrombosis were 92% and 100%, respectively.
CONCLUSION: Our study shows that color Doppler sonography is a reliable way to differentiate between chemical and tumor thromboses of the portal vein in patients with hepatocellular carcinomas treated by ethanol injection. When the sonogram shows pulsatile arterial flow within the thrombus, percutaneous biopsy of the thrombus is unnecessary. The finding is always indicative of malignant thrombosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7717218     DOI: 10.2214/ajr.164.5.7717218

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

Review 1.  Ethanol injection for the treatment of hepatic tumours.

Authors:  C Bartolozzi; R Lencioni
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

2.  Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial.

Authors:  Christian Müller; Maximilian Schöniger-Hekele; Rüdiger Schernthaner; Barbara Renner; Markus Peck-Radosavljevic; Andrea Brichta; Fritz Wrba; Martin Posch; Peter Bauer; Peter Ferenci; Alfred Gangl
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

3.  Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma.

Authors:  Sandro Rossi; Giorgia Ghittoni; Valentina Ravetta; Francesca Torello Viera; Laura Rosa; Martina Serassi; Mara Scabini; Alessandro Vercelli; Carmine Tinelli; Barbara Dal Bello; Peter N Burns; Fabrizio Calliada
Journal:  Eur Radiol       Date:  2008-03-28       Impact factor: 5.315

4.  Contrast-enhanced sonography versus biopsy for the differential diagnosis of thrombosis in hepatocellular carcinoma patients.

Authors:  Paolo Sorrentino; Salvatore D'Angelo; Luciano Tarantino; Umberto Ferbo; Alessandra Bracigliano; Raffaela Vecchione
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

5.  Management of portal vein thrombosis in cirrhotic patients.

Authors:  Lucio Amitrano; Maria Anna Guardascione
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-11-25       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.